A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orternel (TAK-700) Plus Prednisone06/01/2011 - 11/16/2015 (PI)
Millennium Pharmaceuticals, Inc.
A Randomized phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen to Cabazitaxel/Prednisone for second line chemotherapy in men with metastatic castrte resistant prostate cance09/28/2012 - 08/13/2015 (PI)
OncoGenex Technologies, Inc
A phase 3, Randomized, Double-blind, controlled study of cabozantinib (XL184) vs. Prednisone in Metastatic castration resistant prostate cancer patients who have received prior cocetaxel and prior abi10/19/2012 - 10/19/2014 (PI)
Exelixis, Inc
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orternel (TAK-700) Plus Prednisone06/01/2011 - 05/31/2014 (PI)
Millennium Pharmaceuticals, Inc.
DFCI 21-575 - A Phase 2 study of avelumab, axitinib and palbociclib in metastatic renal cell carcinoma03/21/2022 - 03/20/2024 (PI)
Dana Farber Cancer Institute
Precision Interception of Aggressive Prostate Cancer in African American Men09/18/2018 - 08/31/2022 (PI)
Dana Farber Cancer Institute National Cancer Inst5P20CA233255-03
CA209-9KD-07012/03/2018 - 12/03/2021 (PI)
Bristol-Myers Squibb Company
SGN22E-003: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer10/02/2020 - 10/01/2021 (PI)
Seattle Genetics, Inc.
Racial Differences in Androgen Receptor Splice Variants in Men with Localized Prostate Cancer03/01/2018 - 05/31/2021 (PI)
The General Hospital Corporation / MGH Dept of Defense